The newly licensed platform enables precise control over both the drug-to-antibody ratio and payload attachment sites in single- and dual-payload ADCs
AAV vectors are widely used in gene therapy for their strong therapeutic potential
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
Clearance marks major shift beyond chemotherapy
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
With standout ADC and t-cell engager response data across hard-to-treat cancers
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon peptide platform
The company intends to file an IND submission by the end of this year and begin clinical studies in 2027
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
